Support, Education, Research and Advocacy for mast cell disorder patients, physicians, families & caregivers.


Please help us educate and support both people with mast cell diseases (MCD) including mastocytosis, MCAS and HaT, as well as health and medical practitioners. Many people with MCD are provided with limited correct information especially when trying to adjust to their diagnosis. We seek your help with fundraising and developing these resources to make a real difference to these people’s quality of life.


TAMS is a volunteer-run, membership association. TAMS members receive discounts for TAMS conferences and events, member e-newsletters, online and face-to-face support groups and more.

The TAMS committee advocates on behalf of TAMS Members to the medical community and government.


TAMS receives a lot of emails, calls and messages from people seeking diagnosis and treatment for their mast cell dieases. A lot of these ask the same questions, so we have put together some information to help you on your diagnosis and treatment journey.


COVID-19 Vaccine updates

Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination

The ASCIA COVID-19 Working Party has developed guidance about allergy, immunodeficiency, autoimmunity and COVID-19 vaccination. This is updated regularly.


The Australasian Mastocytosis Society (TAMS) has been created as an advocacy, education and support body for those throughout Australasia who suffer from or care for those with Mastocytosis or Mast Cell Activation Syndrome (MCAS). TAMS has been established due to the overwhelming need for sufferers and their supporters to find a local voice and active support network.

TAMS is an independent ‘not for profit’ incorporated organisation with a committed and functional volunteer committee of individuals – all of whom are sufferers or carers – ensuring your needs will be met.


TAMS Support

We provide a network of support for patients living with mast cell disorders including Systemic Mastocytosis, Cutaneous Mastocytosis and Mast Cell Activation Syndrome (MCAS) and their carers.

TAMS runs free monthly online support groups for members and potential members. 
Visit our Facebook Events page for registration information.

Do you suffer from Mastocytosis or MCAD? Join the Australasian Mastocytosis and MCAD Facebook Support Group.

Carers are invited to join the Mastocytosis Australasia Carers Facebook Support Group.


We connect patients

to medical practitioners and specialists with knowledge of Mastocytosis and MCAS.


We link worldwide

with associations to collectively gather research data, share resources and knowledge for greater understanding, treatment practices, medications, improved health outcomes and raising awareness globally.


Why purple?

Why purple?

When mast cells, usually from bone marrow, skin, and GI biopsies, are exposed to a special dye in pathology labs the granules of the mast cell or their cartilage matrix shows up in a distinctive purple colour. Once mast cells are highlighted in purple, pathologists...

read more


Through the building of strong relationships and a greater knowledge base, expand TAMS in geographical and intellectual areas to better support an ever-expanding database of sufferers, their supporters and clinicians.


Mastocytosis has been defined as an abnormal accumulation of mast cells in one or more organ systems. Previously classified by the World Health Organization (WHO) as a myeloproliferative neoplasm, mastocytosis is now classified in its own category under myeloid neoplasms. Broadly separated into three categories, cutaneous mastocytosis (CM), systemic mastocytosis (SM) and mast cell sarcoma. These diseases occur in both children and adults.



The most common form of mastocytosis in children is cutaneous mastocytosis (CM), accounting for approximately 90 percent of mastocytosis cases in this age group. The prognosis is excellent for children with CM who have onset of skin lesions within the first two years of life (most children) as spontaneous resolution or improvement is common after several years. CM that develops after the age of two years tends to persist.


There is an existence of a subset of mast cell disorder patients who experience episodes of mast cell activation without detectable evidence of a proliferative mast cell disorder. Some patients who exhibit symptoms of mast cell mediator release do not fulfil the criteria for SM. Diagnosis requires consistent symptoms, reported benefit with medications and diagnostic evidence of excess mast cells in tissue biopsies or abnormal mast cell mediators in blood or urine tests. This is referred to as Mast Cell Activation Syndrome (MCAS).